PRL Trademark

Trademark Overview

On Monday, October 9, 2023, a trademark application was filed for PRL with the United States Patent and Trademark Office. The USPTO has given the PRL trademark a serial number of 98214461. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Tuesday, April 30, 2024. This trademark is owned by ReNAgade Therapeutics Management, Inc.. The PRL trademark is filed in the Chemical Products, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations, lipids, lipid nanoparticles, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds/agents for medical use; pharmaceutical preparations and therapeutic agents, namely, for RNA, gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation

Chemical and biological agents for scientific and research use, namely, lipids, lipid nanoparticles, lipid formulations, nucleic acids and modified nucleic acids, including short RNAs and messenger RNAs; nucleic acid sequences for scientific purposes, research purposes, and laboratory purposes other than medical and veterinary purposes

Research and development in the field of technology and engineering, lipids, lipid nanoparticles, lipid formulations and RNAs for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of lipids, lipid nanoparticles, lipid formulations, RNAs, namely, developing molecular and cellular biology reagents, techniques, and assays for use in pharmaceutical and biomedical industry
prl

General Information

Serial Number98214461
Word MarkPRL
Filing DateMonday, October 9, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateTuesday, April 30, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical preparations, lipids, lipid nanoparticles, lipid formulations, nucleic acid molecules, enzymes, polypeptides, and compounds/agents for medical use; pharmaceutical preparations and therapeutic agents, namely, for RNA, gene therapy and mRNA regulation; pharmaceutical and biological preparations for medical use for the treatment of genetic and genomic disorders by gene therapy and mRNA regulation for use in human and animal therapeutics; pharmaceutical preparations, namely, therapeutic pharmaceuticals developed through genome modifications for the prevention and treatment of genomic disorders in humans and animals; pharmaceutical preparations for gene therapy and mRNA regulation
Goods and ServicesChemical and biological agents for scientific and research use, namely, lipids, lipid nanoparticles, lipid formulations, nucleic acids and modified nucleic acids, including short RNAs and messenger RNAs; nucleic acid sequences for scientific purposes, research purposes, and laboratory purposes other than medical and veterinary purposes
Goods and ServicesResearch and development in the field of technology and engineering, lipids, lipid nanoparticles, lipid formulations and RNAs for use in gene therapy and mRNA regulation; development of new technology for others for enabling the engineering and modification of lipids, lipid nanoparticles, lipid formulations, RNAs, namely, developing molecular and cellular biology reagents, techniques, and assays for use in pharmaceutical and biomedical industry

Classification Information

International Class001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry.
US Class Codes001, 005, 006, 010, 026, 046
Class Status Code6 - Active
Class Status DateSunday, October 15, 2023
Primary Code001
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSunday, October 15, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateSunday, October 15, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameReNAgade Therapeutics Management, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Tuesday, April 30, 2024NON-FINAL ACTION WRITTEN
Thursday, October 12, 2023NEW APPLICATION ENTERED
Sunday, October 15, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 26, 2024ASSIGNED TO EXAMINER
Tuesday, April 30, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 15, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, July 15, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Tuesday, April 30, 2024NON-FINAL ACTION E-MAILED

Related Keywords

lipid pharmaceutical preparations namely therapy regulation purposes rnas mrna gene